Form Type:  DEFA14A
Filing Date:  4/27/2020 
CIK:  0001426800 
Address:  331 OYSTER POINT BLVD.
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (833) 409-4583 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.24 (1.15%)  
Trade Time: 
02:31 PM EST  
Market Cap: 
Trade ASMB now with 

© 2020  
Description of Business
We are a clinical-stage biotechnology company advancing two innovative programs: a novel class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection and a novel class of oral live microbial biotherapeutic candidates, which are designed to treat disorders associated with the microbiome. Over 250 million people worldwide are chronically infected with HBV. Our HBV Cure program is pursuing multiple drug candidates designed to inhibit the HBV lifecycle and block the generation of covalently closed circular DNA (cccDNA), with the aim of increasing the current low cure rate for patients with HBV. We have discovered several novel core inhibitors, which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein.
Register and access this filing in: